WEDNESDAY, JANUARY 27
Arrival and Registration

THURSDAY, JANUARY 28
Welcome and Keynote Address
Erica Ollmann Saphire, La Jolla Institute for Immunology, USA
Talk Title to be Announced

Therapeutic Antibodies from Patients
Adrian C. Hayday, King’s College London School of Medicine, UK
Patient-Derived Antibodies for Combatting Autoimmune Pathologies Naturally

Stephen Quake, Stanford University, USA
Isolation of Rare Human Plasma Cells: Showcasing Anti-Peanut IgE Antibodies

Pauline M. van Helden, AImm Therapeutics, Netherlands
Mining the B-Cell Repertoire of Cancer Survivors

Short Talks Chosen from Abstracts

Workshop
Short Talks Chosen from Abstracts

Repertoires: Deep Sequencing and Learning
Charlotte Deane, University of Oxford, UK
Deep Learning for Antibody Sequences and Antibody Structures

Pierre Bruhns, Institut Pasteur, France
Human Autoimmune Plasma Cell Repertoires

Tineke Cantaert, Institut Pasteur Cambodia, Cambodia
Protective Anti-Dengue Antibody Responses

Short Talks Chosen from Abstracts

Poster Session 1

FRIDAY, JANUARY 29

Antibodies from Within: Vaccination and Delivery Technologies
Patrick C. Wilson, University of Chicago, USA
Understanding Vaccination: The Influenza Model

Peter D. Kwong, NIAID, National Institutes of Health, USA
Vaccination to Elicit Antibodies Targeting Specific Sites of Vulnerability

Nigel Horscroft, CureVac AG, Germany
mRNA-Based Delivery of Antibodies

Ronald C. Desrosiers, University of Miami Miller School of Medicine, USA
AAV Delivery of Antibodies for Long-Term Protection

Short Talks Chosen from Abstracts

FcRn Exploitation or Targeting
David P. Humphreys, UCB Pharma, UK, UK
IgG FcRn Blockade Therapeutics

Els Louagie, Argenx, Belgium
FcRn Antagonist Efgartigimod for the Treatment of Autoimmune Diseases

Amita Datta-Mannan, Eli Lilly & Company, USA
FcRn Binding Ab Mutants, Peptide Fusions and Glycan Effects

Short Talks Chosen from Abstracts

Poster Session 2

SATURDAY, JANUARY 30

The Rise of Bispecifics
Aran Frank Labrijn, Genmab, Netherlands
Overview on Bispecific Technologies and Platforms

Stefan Weigand, F. Hoffmann La Roche AG, Switzerland
Bispecific Antibodies: Case Studies from Roche’s R&D Pipeline

Mark S. Dennis, Denali Therapeutics, USA
BBB Crossing Bispecific Abs

Bruce Keyt, IGM Biosciences, USA
IgM Bispecifics and Multimers as Therapeutics

Short Talks Chosen from Abstracts

New Tools
Esther Breij, Genmab, Netherlands
Enhanced IgG Hexamerization for Increased Therapeutic Antibody Potency

Sai T. Reddy, ETH Zurich, Switzerland
Engineering an Antigen-Binding Protein by Deep Learning-Guided Directed Evolution

Aaron K. Sato, Twist Bioscience, USA
High Throughput Synthetic DNA Technologies Enable Antibody Discovery and Optimization

Short Talks Chosen from Abstracts

Novel Therapeutic Antibodies in the Clinic
Cecile Geuijen, Merus NV, Netherlands
The Use of Unbiased Screens to Identify Therapeutic Bispecific Antibodies

Eric Vivier, Aix Marseille University, France
Exploiting NK Cells to Induce Anti-Tumor Response in Preclinical and Clinical Setting

Neil Brewis, F-star Biotechnology Ltd., UK
Immuno-Oncology Therapeutics (including OX40x4-1BB Bispecifics)

Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

SUNDAY, JANUARY 31

Departure